Lonza

184 articles with Lonza

• Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab

  7/31/2019

  Omeros and Lonza have successfully partnered under a multi-year manufacturing agreement for the clinical supply of narsoplimab.

• Lonza Expands Bioconjugation Facility and Announces Approval of Third Commercial ADC

  7/24/2019

  Expansion to bioconjugation facility in Visp, Switzerland to meet increasing clinical, launch and commercial market demand

• Lonza on Track to Deliver Full-Year 2019 Results, Driven by Pharma Biotech Business

  7/24/2019

  Double-digit sales growth delivered by Pharma Biotech & Nutrition (LPBN) segment

• 

  Lonza Snaps up Drug Production Facility From Novartis

  7/1/2019

  Financial details of the deal were not disclosed, but Lonza said it plans to retain the Novartis employees currently working at the facility.

• Lonza Publishes Restated Financials for 2018

  6/20/2019

  Lonza reports restated 2018 financials for sales, CORE EBITDA and CORE EBIT

• Carve-out of Lonza Specialty Ingredients will help segment to become a global leader in microbial control

  6/3/2019

  Lonza Group announced its intention to proceed with a carve-out of its Specialty Ingredients segment.

• Pharma Biotech and Nutrition Businesses Continue to Drive Lonza Performance in Q1 2019

  4/18/2019

  All investments in healthcare businesses progressing as planned to further accelerate growth

• Lonza Provides Adjusted Mid-Term Guidance and Emphasizes Growth Along the Healthcare Continuum®

  3/4/2019

  Lonza announced the adjustment of its Mid-Term Guidance 2022 to reflect the divestment of its former Water Care business unit and to emphasize Lonza's focus on growth along the Healthcare Continuum®.

• Lonza Completes Divestment of Water Care Business

  3/1/2019

  Lonza announced the completion of the divestment of its former Water Care business and operations to Platinum Equity for USD 630 million.

• Lonza Strengthens Pharma, Biotech and Nutrition Offerings with Aligned Structure and New Executive Committee Appointment

  2/25/2019

  Lonza announced the internal alignment of its business structure to accelerate growth along the Healthcare Continuum® and strengthen the Microbial Control business.

• Lonza Announces Succession of CEO

  1/30/2019

  Lonza announced that Richard Ridinger, CEO, has decided to retire from the company after seven successful years.

• Lonza Achieved Another Excellent Full-Year Result in 2018 with 9% Organic Sales Growth and Strong Profitability Driven by Healthcare Businesses

  1/30/2019

  Lonza reported a 9% organic sales, 12% organic CORE EBITDA and 14% organic CORE EBIT growth.

• Lonza Announces Retirement of Fridtjof Helemann

  1/15/2019

  Fridtjof Helemann will leave the company on 31 March 2019, upon reaching retirement age.

• Lonza Publishes IFRS 15 Adoption and Pro-Forma Numbers for Full-Year 2017 for Its Continuing Operations, Excluding Water Care Business

  12/19/2018

  Lonza today is publishing unaudited Full-Year 2017 information excluding the Water Care business and taking into consideration additional reporting-related items to enable comparison and inform capital market participants about the upcoming reporting changes prior to our Full-Year 2018 results publication.

• ERS Genomics and Lonza Enter Into CRISPR/Cas9 Technology Licensing Deal

  12/13/2018

  ERS Genomics Limited and Lonza Pharma & Biotech announced today a license agreement to provide Lonza with access to ERS Genomics’ CRISPR/Cas9 genome editing technology patents.

• Lonza to Establish Strategic Biomanufacturing Base in China Using GE Healthcare Solution

  12/10/2018

  New biologics facility, scheduled to be operational in 2020, will provide development and manufacturing facilities from early- to late-clinical and early-commercial stages

• Lonza Further Strengthens Focus on Its Healthcare Continuum Strategy by Signing Agreement to Divest Water Care Business to Platinum Equity

  11/1/2018

  Lonza and Platinum Equity jointly announced today that Platinum Equity has entered into a definitive agreement with Lonza to acquire Lonza's Water Care business and operations for USD 630 million.

• Lonza Acquires a Controlling Stake in Octane Biotech to Further Develop CocoonTM Autologous Technology

  10/29/2018

  Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies

• Lonza Continues Strong Momentum in Businesses Along the Healthcare Continuum in Q3 2018 and Confirms Positive Outlook for the Full Year

  10/25/2018

  Businesses in Pharma & Biotech and in Consumer Health – including capsule and combined ingredient and dosage form offerings – continued to drive growth

• Lonza's Capital Markets Day 2018 Outlines Sustainable Growth Plans Through Focus and Investment

  9/25/2018

  Lonza is holding a series of events as part of this year's Capital Markets Day from 24-26 September in Zurich and Visp (CH).